This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Review

. 1993 Mar 15;81(6):1414-23.

Lowest dose interleukin-2 immunotherapy

K A Smith¹

Affiliations

PMID: 8453090

Free article

Review

Lowest dose interleukin-2 immunotherapy

K A Smith. Blood. 1993.

Free article

. 1993 Mar 15;81(6):1414-23.

Author

K A Smith¹

Affiliation

¹ Department of Medicine, Dartmouth Medical School, Hanover, NH 03755-3833.

PMID: 8453090

No abstract available

PubMed Disclaimer

Comment in

CD39 as a novel marker of in vivo immune activation.
Duensing S, Kirshner H, Atzpodien J. Duensing S, et al. Blood. 1994 Jun 15;83(12):3826-7. Blood. 1994. PMID: 8204900 No abstract available.

Similar articles

[Biological properties and therapeutic use of interleukin 2 (IL-2)].
Robak T. Robak T. Postepy Hig Med Dosw. 1995;49(3):367-93. Postepy Hig Med Dosw. 1995. PMID: 8657637 Review. Polish.
Rational immunotherapy with interleukin 2.
Kaplan G, Cohn ZA, Smith KA. Kaplan G, et al. Biotechnology (N Y). 1992 Feb;10(2):157-62. doi: 10.1038/nbt0292-157. Biotechnology (N Y). 1992. PMID: 1368227 Review.
Human interleukin 2: molecular biology, physiology and clinical possibilities.
Mertelsmann R, Welte K. Mertelsmann R, et al. Immunobiology. 1986 Sep;172(3-5):400-19. doi: 10.1016/S0171-2985(86)80121-8. Immunobiology. 1986. PMID: 3100434 Review. No abstract available.
Human interleukin 2: biochemistry, physiology, and possible pathogenetic role in immunodeficiency syndromes.
Welte K, Mertelsmann R. Welte K, et al. Cancer Invest. 1985;3(1):35-49. doi: 10.3109/07357908509040606. Cancer Invest. 1985. PMID: 3918772 Review. No abstract available.
IL-15 in the life and death of lymphocytes: immunotherapeutic implications.
Waldmann TA. Waldmann TA. Trends Mol Med. 2003 Dec;9(12):517-21. doi: 10.1016/j.molmed.2003.10.005. Trends Mol Med. 2003. PMID: 14659465 Review. No abstract available.

See all similar articles

Cited by

X-linked severe combined immunodeficiency disease and the gamma c receptor component: prospects for molecular diagnosis.
Farner NL, Voss SD, Sondel PM. Farner NL, et al. Clin Diagn Lab Immunol. 1995 Sep;2(5):518-23. doi: 10.1128/cdli.2.5.518-523.1995. Clin Diagn Lab Immunol. 1995. PMID: 8548528 Free PMC article. Review. No abstract available.
Interleukin-2. A review of its pharmacological properties and therapeutic use in patients with cancer.
Whittington R, Faulds D. Whittington R, et al. Drugs. 1993 Sep;46(3):446-514. doi: 10.2165/00003495-199346030-00009. Drugs. 1993. PMID: 7693434 Review.
A risk-benefit assessment of interleukin-2 as an adjunct to antiviral therapy in HIV infection.
Piscitelli SC, Bhat N, Pau A. Piscitelli SC, et al. Drug Saf. 2000 Jan;22(1):19-31. doi: 10.2165/00002018-200022010-00003. Drug Saf. 2000. PMID: 10647974 Review.
Prolonged low dose IL-2 and thalidomide in progressive metastatic renal cell carcinoma with concurrent radiotherapy to bone and/or soft tissue metastasis: a phase II study.
Kerst JM, Bex A, Mallo H, Dewit L, Haanen JB, Boogerd W, Teertstra HJ, de Gast GC. Kerst JM, et al. Cancer Immunol Immunother. 2005 Sep;54(9):926-31. doi: 10.1007/s00262-005-0677-2. Epub 2005 May 19. Cancer Immunol Immunother. 2005. PMID: 15906025 Free PMC article. Clinical Trial.
Prostate-specific membrane antigen-based therapeutics.
Akhtar NH, Pail O, Saran A, Tyrell L, Tagawa ST. Akhtar NH, et al. Adv Urol. 2012;2012:973820. doi: 10.1155/2012/973820. Epub 2011 Jul 17. Adv Urol. 2012. PMID: 21811498 Free PMC article.

See all "Cited by" articles

Publication types

Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions

LinkOut - more resources

Full Text Sources
- Elsevier Science
Other Literature Sources
- The Lens - Patent Citations Database